Despite the shortcomings of current therapies—which are only
moderately effective and often impose a high side-effect burden—the market for
overactive bladder (OAB) drugs has grown significantly and steadily over the
last ten or more years. As a result, it is an attractive environment for drug
companies, who persevere in the face of recent OAB clinical failures to develop
novel therapies that capitalize on physicians’ eagerness for more-effective
drugs with novel mechanisms of action.
Markets: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 22 country-specific interviews with urologists, urogynecologists, and GP/PCPs.
Epidemiology: Total prevalent cases of OAB; prevalent cases of OAB by symptom, including urinary incontinence, urinary frequency, and nocturia.
Emerging therapies: Phase II: eight drugs; Phase III: two drugs; preregistration: one drug. Coverage of select preclinical and Phase I products.
Market forecast features: Using a proprietary analogue generic erosion model and anticipated launch dates based on primary and secondary research, we forecast drug sales for the treatment of OAB through 2019.